-transparent.png){kind=logo}
The objective of this survey was to describe life insurance underwriting practices concerning children with asymptomatic hematuria and proteinuria. A questionnaire was sent to 200 companies licensed to issue life insurance policies in the state of New York. The medical director of each company was asked to respond to the insurability of children with asymptomatic hematuria and proteinuria. Two case summaries were provided with the questionnaire. Of 97 companies, 66 would offer insurance to the patient with hematuria, although 38 (58%) would charge additional premiums. In response to the problem of proteinuria, 61 companies would offer life insurance, although 50 (82%) would require higher premium charges (P < 0.002 compared with hematuria). We conclude that children with asymptomatic hematuria and proteinuria can usually obtain life insurance, although often at higher cost. Invasive diagnostic tests are not necessary for insurers to offer insurance.
L G Feld, and
F B Stapleton
May 1997,
The Medical clinics of North America,
L G Feld, and
F B Stapleton
May 1983,
Delaware medical journal,
L G Feld, and
F B Stapleton
February 1988,
Nederlands tijdschrift voor geneeskunde,
L G Feld, and
F B Stapleton
February 2005,
Revue medicale suisse,
L G Feld, and
F B Stapleton
March 1988,
Nederlands tijdschrift voor geneeskunde,
L G Feld, and
F B Stapleton
November 1974,
Archives of internal medicine,
L G Feld, and
F B Stapleton
October 2002,
The Journal of the Arkansas Medical Society,
L G Feld, and
F B Stapleton
December 1978,
Postgraduate medicine,
L G Feld, and
F B Stapleton
May 1970,
L'union medicale du Canada,
